Therapieabbau bei stabil eingestellter rheumatoider Arthritis

Allaart CF, Lems WF, Huizinga TWJ (2013) The BeSt way of withdrawing biologic agents. Clin Exp Rheumatol 31(Suppl 78):S14–S18 Brocq O, Millasseau E, Albert C et al (2009) Effect of discontinuing TNFa antagonist therapy in patients with remission of rheumatoid arthritis. Joint Bone Spine 76:350–355 Detert J, Bastian H, Listing J et al (2013) Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naïve patients with early rheumatoid arthritis: HIT HARD, an investigator-initiated study. Ann Rheum Dis 72:844–850 Emery P, Hammoudeh M, FitzGerald O et al (2014) Sustained remission with etanercept tapering in early rheumatoid arthritis. N Engl J Med 371:1781–1792 Emery P, Burmester GR, Bykerk VP et al (2015) Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period. Ann Rheum Dis 74:19–26 Haschka J, Englbrecht M, Hueber AJ et al (2015) Relapse rates in patients with rheumatoid arthritis in stable remission tapering or stopping antirheumatic therapy: interim results from the prospective randomised controlled RETRO study. Ann Rheum Dis (online first Feb 6, 10.1136/annrheumdis-2014-206439) Huizinga TWJ, Conaghan PG, Martin-Mola E et al (2015) Clinical and radiographic outcomes at 2 years and the effect of tocilizumab discontinuation following sustained remission in the second and third year of the ACT-RAY study. Ann Rheum Dis 74:35–43 Iwamoto T, Ikeda K, Hosokawa J et al (2014) Prediction of relapse after discontinuation of biologic agents by ultrasonographic assessment in patients with rheumatoid arthritis in clinical remission: high predictive values of total gray-scale and power Doppler scores that represent residual synovial inflammation before discontinuation. Arthritis Care Res 66:1576–1581 Krüger K, Wollenhaupt J, Albrecht K et al (2012) S1-Leitlinie der DGRh zur sequenziellen medikamentösen Therapie der rheumatoiden Arthritis 2012: adaptierte EULAR Empfehlungen und aktualisierter Therapiealgorithmus. Z Rheumatol 71:592–603 Marks JL, Holroyd CR, Dimitrov BD et al (2015) Does combined clinical and ultrasound assessment allow selection of individuals with rheumatoid arthritis for sustained reduction of anti-TNF therapy? Arthritis Care Res. doi:10.1002/acr.22552 O’Mahony R, Richards A, Deighton C et al (2010) Withdrawal of disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a systematic review and meta-analysis. Ann Rheum Dis 69:1823–1826 Pope JE, Haraoui B, Thorne JC et al (2014) The Canadian Methotrexate and Etanercept Outcome Study: a randomised trial of discontinuing versus continuing methotrexate after 6 months of etanercept and methotrexate therapy in rheumatoid arthritis. Ann Rheum Dis 73:2144–2151 Quinn MA, Conaghan PG, O’Connor PJ et al (2005) Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal. Arthritis Rheum 52:27–35 Raffeiner B, Botsios C, Ometto F et al (2015) Effects of half dose etanercept (25 mg once a week) on clinical remission and radiographic progression in patients with rheumatoid arthritis in clinical remission achieved with standard dose. Clin Exp Rheumatol 33:63–68 Saleem B, Keen H, Goeb V et al (2010) Patients with RA in remission on TNF blockers: when and in whom can TNF blocker therapy be stopped? Ann Rheum Dis 69:1636–1642 Smolen JS, Nasch P, Durez P et al (2013) Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. Lancet 381:918–929 Smolen JS, Emery P, Fleischmann R et al (2014) Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial. Lancet 383:321–332 Smolen JS, Landewé R, Breedveld FC et al (2014) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 73:492–509 Smolen JS, Emery P, Ferraccioli GF et al (2015) Certolizumab pegol in rheumatoid arthritis patients with low to moderate activity: the CERTAIN double-blind, randomised, placebo-controlled trial. Ann Rheum Dis 74:843–850 Takeuchi T, Matsubara T, Ohta S et al (2015) Biologic-free remission of established rheumatoid arthritis after discontinuation of abatacept: a prospective, multicentre, observational study in Japan. Rheumatology 54:683–691 Tanaka Y, Takeuchi T, Mimori T et al (2010) Discontinuation of infl iximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study. Ann Rheum Dis 69:1286–1291 Tanaka Y, Hirata S, Kubo S et al (2015) Discontinuation of adalimumab after achieving remission in patients with established rheumatoidarthritis: 1-year outcome of the HONOR study. Ann Rheum Dis 74:389–395 Ten Wolde S, Breedveld FC, Hermans J et al (1996) Randomised placebo-controlled study of stopping second-line drugs in rheumatoid arthritis. Lancet 347:347–352 Van der Maas A, Kievit W, Bernt JF van den et al (2012) Down-titration and discontinuation of infliximab in rheumatoid arthritis patients with stable low disease activity and stable treatment: an observational cohort study. Ann Rheum Dis 71:1849–1854 Van der Nies JAB, Tsonaka R, Gaujoux-Viala C et al (2015) Evaluating relationships between symptom duration and persistence of rheumatoid arthritis: does a window of opportunity exist? Results on the Leiden Early Arthritis Clinic and ESPOIR cohorts. Ann Rheum Dis 74:806–812 Van der Woude D, Young A, Jayakumar K et al (2009) Prevalence of and predictive factors for sustained disease-modifying antirheumatic drug-free remission in rheumatoid arthritis. Arthritis Rheum 60:2262–2271 Van Herwaarden N, Herfkens-Hol S, Maas A van der et al (2014) Dose reduction of tocilizumab in rheumatoid arthritis patients with low disease activity. Clin Exp Rheumatol 32:390–394 Yamanaka H, Seto Y, Nagaoka S et al. (2014) Discontinuation of Etanercept in early rheumatoid arthritis patients who have achieved sustained remission: results of the randomized controlled trial in period 2 of the Entourage study. Ann Rheum Dis 73(Suppl):THU0169 Yoshida K, Sung YK, Kavanaugh A et al (2014) Biologic discontinuation studies: a systematic review of methods. Ann Rheum Dis 73:595–599